| Range: | 5.93-38.12 | Vol Avg: | 1137389 | Last Div: | 0 | Changes: | 0.22 |
| Beta: | 0.15 | Cap: | 3.05B | Currency: | USD | Exchange: | NASDAQ |
| Sector: | Healthcare | IPO: | Fri Mar 26 2021 | Empoloyees: | 108 | ||
| CUSIP: | 28036F105 | CIK: | 0001710072 | ISIN: | US28036F1057 | Country: | US |
| CEO: | Dr. Kevin Koch Ph.D. | Website: | https://www.edgewisetx.com | ||||
EWTX 32.20 Stock Price Edgewise Therapeutics, Inc.
Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The Company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy which has completed Phase 1 clinical trial. It develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.
Stock Details
Negative -0.19
Analysts Think There's Still Time To Get In On Edgewise
Edgewise Therapeutics EWTX is a small-cap pharmaceutical stock that has been all the rage ...
benzinga.com·Mon Sep 30 2024
Positive 0.28
Edgewise Therapeutics Soars 50%: Key Reasons Behind the Surge
Edgewise Therapeutics EWTX is up 50% in a single session and 450% from recent lows for a r...
benzinga.com·Wed Sep 25 2024
Negative -0.19
Analyst Think There's Still Time to Get in on Edgewise, Up 332%
Edgewise Therapeutics NASDAQ: EWTX is a small-cap pharmaceutical stock that has been all t...
marketbeat.com·Wed Sep 25 2024
Positive 0.28
Edgewise Therapeutics Soars 50%: Key Reasons Behind the Surge
Edgewise Therapeutics NASDAQ: EWTX is up 50% in a single session and 450% from recent lows...
marketbeat.com·Thu Sep 19 2024
Neutral -0.10
Why Edgewise Therapeutics Stock Is Up 50% on Thursday
Edgewise's EDG-7500 shows promise as a treatment for hypertrophic cardiomyopathy. This mar...
fool.com·Thu Sep 19 2024
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow